About
Molecule.one is a TechBio company that has built Maria™, a high-throughput robotic synthesis platform orchestrated by frontier AI. By conducting over 300,000 microliter experiments, the platform has mapped chemical reactivity far beyond human intuition, enabling superhuman synthesis success rates across a highly diverse set of building blocks. The platform serves pharmaceutical companies and biotechs in two primary ways. First, through its on-demand molecule service, customers can order novel, purified compounds from SpaceM1—a library of 70M+ virtual compounds—at the <1 mg or 1–10 mg scale, with the fastest tier shipping in 7 working days. For projects with a defined target and assay, an end-to-end discovery service delivers confirmed biological hits in as little as 4 weeks. Second, Molecule.one licenses Maria's AI models—including M1 RetroScore (powered by CAS) for retrosynthesis planning and reaction condition recommendation—directly into in-house chemistry workflows, enabling research teams to make faster, better synthesis decisions. Custom AI models trained on bespoke HTE data can also be developed to solve unique chemistry challenges. Molecule.one is trusted by top pharma companies, biotechs, and industrial leaders such as W. R. Grace & Co., and has published peer-reviewed research in JCIM. It is well-suited for medicinal chemists, drug discovery teams, fine chemical manufacturers, and any organization looking to reduce CRO costs while accessing greater compound diversity.
Key Features
- Maria™ AI Synthesis Platform: A high-throughput robotic synthesis platform trained on 300,000+ microliter experiments, achieving superhuman synthesis success rates across a diverse set of building blocks.
- On-Demand Molecule Delivery: Order diverse, novel, purified compounds from the SpaceM1 library (70M+ virtual compounds) at the <1 mg or 1–10 mg scale, shipped in as little as 7 working days.
- End-to-End Hit Discovery: Full discovery service from design to biological validation—delivering confirmed novel hits in 4 weeks for well-defined targets and assays.
- AI Retrosynthesis & Condition Recommendation: License M1 RetroScore (powered by CAS) and condition recommendation models to integrate world-class retrosynthesis planning directly into in-house chemistry workflows.
- Custom AI Model Development: Develop bespoke AI models trained on custom HTE data to overcome persistent chemistry roadblocks and discover novel reaction conditions.
Use Cases
- Pharmaceutical R&D teams ordering novel, purified hit compounds to accelerate early-stage drug discovery without scaling in-house synthesis.
- Biotech companies running end-to-end hit discovery campaigns—from target selection to confirmed biological activity—within a 4-week timeline.
- Medicinal chemistry departments licensing Maria's AI retrosynthesis models to improve synthesis planning efficiency and reduce CRO dependency.
- Fine chemical and specialty materials manufacturers using AI and HTE automation to discover novel reaction conditions for complex synthesis challenges.
- Drug discovery organizations seeking greater building block diversity and synthesis success rates compared to traditional CRO or on-demand compound providers.
Pros
- Exceptional Speed and Turnaround: Novel purified molecules delivered in 7 working days and end-to-end biological hits in 4 weeks—significantly faster than traditional CRO pipelines.
- Superior Compound Diversity: Access to 70M+ virtual compounds with building block diversity and chemistry breadth that rivals or surpasses leading industrial suppliers.
- Flexible Engagement Models: Customers can order individual compounds, leverage a full discovery service, or license the AI platform for internal use—suiting a wide range of organizational needs.
- Validated by Industry Leaders: Trusted and publicly endorsed by top pharma companies, W. R. Grace & Co., and Osmo, with peer-reviewed research backing the underlying technology.
Cons
- Enterprise-Focused Pricing: Services are primarily quote-based and aimed at pharma/biotech organizations, making costs opaque and potentially prohibitive for academic or small-scale users.
- Narrow Domain Focus: The platform is highly specialized in small molecule chemistry and drug discovery, limiting applicability outside pharmaceutical and fine chemical industries.
- Integration Requirements: Licensing Maria™ for in-house use requires integration into existing chemistry workflows, which may demand technical resources and onboarding time.
Frequently Asked Questions
What is Maria™?
Maria™ is Molecule.one's flagship AI-powered high-throughput robotic synthesis platform. It was trained on over 300,000 microliter experiments to map chemical reactivity, enabling it to design synthesis plans and achieve high success rates using a diverse range of building blocks.
How quickly can I receive synthesized compounds?
The fastest tier of the on-demand service ships purified compounds in 7 working days. For the end-to-end hit discovery service, confirmed biologically active hits are typically delivered within 4 weeks.
Can I license the AI models for use within my own organization?
Yes. Molecule.one offers licensing of Maria's AI, including the M1 RetroScore retrosynthesis model (powered by CAS) and reaction condition recommendation models, for integration into in-house chemistry workflows.
What is SpaceM1?
SpaceM1 is Molecule.one's proprietary virtual compound library containing 70M+ synthesizable compounds. It is the source from which on-demand orders are fulfilled, offering broad chemical diversity beyond typical on-demand compound spaces.
Is there a free trial available?
Yes, a free trial is available for M1 RetroScore, the AI retrosynthesis planning tool powered by CAS. Full platform licensing and the molecule synthesis services are available via a custom quote.
